LEISHIELD PILOT

groupe_leishield-Pilot.jpeg

ABOUT LEISHIELD

Protozoan parasites of the genus Leishmania generate severe human diseases termed Leishmaniases. Due to their frequency and the severity of certain clinical forms, these diseases represent a major public health problem and limit the economic growth in various developing countries. 

situation-Pilot.jpeg

LEISHMANIA SITUATION

Chemotherapy remains the most important element in the control of VL as there are currently no vaccines to prevent VL infection. All current treatments suffer from significant drawbacks, i.e. parenteral route of administration, length of treatment (21 to 28 days), toxicity, or/and cost which limits their utilisation in disease endemic areas.

flag-of-Europe.PNG

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°778298.